Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Quad’s Side Effects Profile, Novel Agents To Get Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Antiviral Drugs Advisory Committee takes up the four-drug HIV-1 regimen, which includes two new agents, on May 11. The firm hopes to be able to sell the combination in part on its favorable side effects profile if the product is approved.

You may also be interested in...



Medicines Patent Pool/BMS Deal On Atazanavir To Benefit 110 Developing Countries, But Not China And Brazil

The Medicines Patent Pool’s deal with BMS for licenses for the manufacture and supply of atazanavir for low- to middle-income countries will benefit up to a million HIV sufferers.

110 Countries Benefit From Medicines Patent Pool/BMS Deal On Atazanavir

The Medicines Patent Pool’s deal with BMS for licenses for the manufacture and supply of atazanavir for low- to middle-income countries will benefit up to a million HIV sufferers.

Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results

Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel